metaPreg - Isradipine (versus unexposed) during pregnancy

Isradipine (versus unexposed) updated on 03-11-2025

Table Graphic exposition period:

Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Maternal consequences
Assisted deliveries (forceps, vacuum, ...)	1.90 [0.46, 7.85]	28%	2 studies	16	86	not evaluable	ROB	-
Caesarean	1.49 [0.71, 3.15]	0%	2 studies	61	86	not evaluable	ROB	-
Neonatal disorders
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Neonatal hypoglycemia	4.00 [1.06, 15.08]	-	1 study	28	39	not evaluable	ROB	7.46 [1.32; .]
4 non statistically significant endpoints reported in only one study